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Abstract
Over the past two decades Russia has gone through dramatic 'democratic' changes resulting in
unprecedented deterioration of health, loss of lives and extinction of population. The health
system turned into a ridiculous monster of poorly organized business exploiting reminiscent
social values of the past to build profits on selling sickness-for-all in consumer culture. We
present facts and conclude that introduction of palivizumab into clinical practice for the most
vulnerable  patient  category  was  done  without  confirmation  of  efficacy,  without
pharmacoeconomics  evaluations,  without  any  precautionary  measures  in  a  country  with
undeveloped pharmacovigilance system. The situation calls for immediate action of responsible
authorities and the society as a whole. © 2014-IOS Press and the authors.
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